James E. Levine

This profile gathers the share dealings of James E. Levine across 3 companies, led by Cardiff Oncology, Inc., Diversa Corp and Cidara Therapeutics, Inc. Between 6 May 2009 and 18 December 2024, the trades on record add up to 21 filings.

Every open-market trade on record is a purchase: 17 purchases worth €632k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 3 share grants. So far in 2024, the count stands at 3 purchases and no sales.

In size, the median ticket on the buying side is €30k. 6 out of 12 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The record was last updated on 18 December 2024 with an open-market purchase (€14k) in Cardiff Oncology, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.